Vandetanib Give Medullary Thyroid Cancer Patients A Second Chance

submitted by: mdanderson

In April, the U.S. Food and Drug Administration approved the use of vandetanib for the treatment of medullary thyroid carcinoma. MD Anderson's Dr. Robert Gagel who with his team helped to bring about the FDA's approval of vandetanib talks about the drug, the research and it's benefit to medullary thyroid cancer patients.